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Abstract
Introduction—Diadenosine 5',5"'-P1,P4-tetraphosphate (Ap4A) is stored in platelet dense granules,
but its effects on platelet function are not well understood.
Methods and Results—We examined the effects of Ap4A on platelet purinergic receptors
P2Y1, P2Y12 and P2X1. Flow cytometry was used to measure the effects of Ap4A in the presence or
absence of ADP on: a) P2Y12-mediated decrease in intraplatelet phosphorylated vasodilator
stimulated phosphoprotein (VASP), b) P2Y1-mediated increase in platelet cytosolic Ca2+, and c)
P2X1-mediated intraplatelet entry of extracellular Ca2+. ADP-stimulated platelet shape change
(P2Y1-mediated) and aggregation (P2Y1- and P2Y12-mediated) were measured optically. Ap4A
inhibited 3 µM ADP-induced: a) platelet aggregation (IC50 9.8 ± 2.8 µM), b) P2Y1-mediated shape
change, c) P2Y1-mediated increase in platelet cytosolic Ca2+ (IC50 40.8 ± 12.3 µM), and d) P2Y12-
mediated decrease in VASP phosphorylation (IC50 >250 µM). In the absence of added ADP, Ap4A
had agonist effects on platelet P2X1 and P2Y12, but not P2Y1, receptors.
Conclusion—Ap4A, a constituent of platelet dense granules, is a) an antagonist of platelet P2Y1
and P2Y12 receptors, where it inhibits the effects of ADP, and b) an agonist of platelet P2X1 and
P2Y12 receptors.
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Introduction
Platelets express three purinergic receptors, P2X1, P2Y1 and P2Y12 (Fig. 1).[1,2] P2X1
receptors are activated by adenosine 5’-triphosphate (ATP) while P2Y1 and P2Y12 receptors
are both activated by adenosine 5'-diphosphate (ADP) [1,2]. The P2X1 receptor is a ligand-
gated ion channel which upon activation triggers fast influx of extracellular Ca2+ into the
cytoplasm and transient platelet shape change (Fig. 1) [1–4]. P2Y1 and P2Y12 are G-protein
coupled receptors, P2Y1 being coupled to Gq and P2Y12 to Gi[1,2]. Upon activation, P2Y1
triggers Ca2+ mobilization from the platelet dense tubular system, shape change, and reversible
platelet aggregation (Fig. 1) [1,2]. Activation of P2Y12 leads to inhibition of the adenylyl
cyclase-dependent production of cytoplasmic cyclic adenosine 5'-monophosphate (cAMP) and
propagation of stable platelet aggregation [1,2]. cAMP activates protein kinase A which then
phosphorylates vasodilator stimulated protein (VASP) [2,5], a modulator of platelet cytosolic
proteins (Fig. 1). Both P2Y1 and P2Y12 play major roles in the amplification and stabilization
of platelet activation. The exact physiological role of P2X1 is less clear, but it plays a role in
the enhancement of the effect of low levels of primary platelet activators and in high shear
stress activation [1,2].
Diadenosine 5',5"'-P1,P4-tetraphosphate (Ap4A) and other diadenosine polyphosphates are
naturally occurring compounds that are ubiquitous in mammalian tissues[6], including human
platelets[7,8]. They may serve as neurotransmitters[9] and modulators of vascular tone
[10].There is growing evidence that Ap4A plays a role in systemic diseases such as diabetes
mellitus and hypertension [11,12]. In platelets, Ap4A is stored in dense granules, and is
therefore released along with ADP and ATP upon platelet activation[8,13]. Ap4A and its
analogs are known to inhibit ADP-induced platelet activation[14,15]. Ap4A analogs inhibit the
ADP-induced platelet release reaction, calcium mobilization, thromboxane production and
platelet factor 3 activities[14]. However, these studies[14,15] were performed before all three
platelet purinergic receptors were cloned and their functions characterized. Therefore, the
mechanism by which Ap4A inhibits ADP-induced platelet activation and its possible effects
on P2Y1 and P2Y12 are unknown. Diadenosine polyphosphates are potent agonists of P2X
receptors expressed on a variety of human and rat cell types[16,17]. Although human platelets
express P2X1 receptors[18–20], whether Ap4A is an agonist via platelet P2X1 is unknown.
The goal of the present study was, therefore, to elucidate the effects of Ap4A on signaling
through P2Y1, P2Y12 and P2X1 receptors on human platelets. We demonstrate that Ap4A, a
known constituent of platelet dense granules, is: a) an antagonist of platelet P2Y1 and P2Y12
receptors, where it inhibits the effects of the agonist ADP, b) an agonist of P2X1 receptors, and
c) a partial agonist of P2Y12 receptors.
Materials and Methods
Chemicals and reagents
Ap4A was synthesized by a novel method (to be published) and was >98% pure by reverse
phase HPLC. MRS2179, MRS2159, probenecid, adenosine 5'-(β,γ-methylene)triphosphate
(β,γ-CH2-ATP) and apyrase (grade VII) were purchased from Sigma-Aldrich (St. Louis, MO).
D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) was purchased from
Calbiochem (EMD Biosciences, La Jolla, CA). FLUO-4 was from Invitrogen (Carlsbad,
CA),ADP was from Bio/Data (Horsham, PA), CD41-phycoerythrin (PE)-Cy5 was from
Beckman Coulter (Fullerton, CA), and AR-C69931 was from AstraZeneca (Charnwood, UK).
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Blood collection and sample preparation
Human blood samples were taken from healthy volunteer donors who had been free from
aspirin or other non-steroidal anti-inflammatory drugs for more than 7 days. IRB-approved
written informed consent was obtained before blood collection. Unless otherwise specified,
blood was drawn from antecubital veins into 3.2% sodium citrate tubes. Whole blood was used
in VASP phosphorylation and P2Y1 cytosolic Ca2+ assays. For platelet aggregation tests, the
blood was centrifuged at 110 g for 12 minutes and platelet-rich plasma (PRP) was immediately
removed. The remaining samples were further centrifuged at 1650 g for 10 minutes to obtain
platelet-poor plasma (PPP), which was used as a reference. For assays of platelet P2X1 receptor
functions, whole blood was drawn into tubes containing PPACK (0.3 mM, final concentration)
and apyrase (1.8 µM final concentration). The samples were then centrifuged and processed
to retrieve PRP and PPP.
ADP-induced platelet aggregation and shape change
Light transmission platelet aggregation was performed as previously described[21]. ADP (3
µM) in the presence or absence of various concentrations of Ap4A was added to PRP, and the
aggregation response was recorded for a total of six minutes in a Chrono-log® aggregometer
running the Aggro/Link software (Chrono-log®, Havertown, PA).
For observation of ADP-induced platelet shape change, EDTA (final concentration 10 mM)
was mixed with PRP to allow ADP-induced shape change but to avoid platelet-platelet
aggregation. After obtaining a stable baseline tracing in the aggregometer ADP (3 µM), in the
presence or absence of various concentrations of Ap4A, was added to induce platelet shape
change, and the tracing recorded for a total of 4 minutes.
Platelet aggregation measured by microplate reader
The 96-well microplate method for the detection of platelet aggregation is a simple, rapid, low
volume method to simultaneously measure platelet aggregation of multiple samples, thereby
avoiding the variable of platelet aging[22,23]. In brief, ADP (5 µL, final concentration 3 µM)
and Ap4A (5 µL, at various concentrations) were added to each well of a flat bottom 96-well
Immulon microplate (Thermo Fisher Scientific, Waltham, MA). PRP (90 µL) was then added
to each well with a multi-channel pipette, and light transmission was recorded with a Molecular
Devices microplate reader, running SOFTmax Pro 4.0 software at 580 nm wavelength under
the kinetic mode, with intermittent shaking and readings every 11 seconds at 37°C. Results of
platelet aggregation measured by the microplate method have been demonstrated to be
comparable to results of conventional platelet aggregation[22,23]. Similarly, we observed
comparable Ap4A inhibition of ADP-stimulated platelet aggregation by these two methods in
the present study (Figure 2A and 2B). Since the microplate method avoids possible aging
artifacts, results from this method were used to calculate the IC50 for Ap4A.
P2Y12-mediated VASP phosphorylation assay
VASP phosphorylation (Fig. 1) was measured by flow cytometry[5] using a kit (BioCytex,
Marseilles, France) essentially according to the manufacturer’s recommendations. In brief,
Ap4A or vehicle (2 µL) was added to each set of assay tubes, followed by prostaglandin E1
(PGE1, 9 µL) or the same volume of PGE1 plus ADP. Citrated whole blood (10 µL) was then
added to each tube, and the samples were incubated for 10 minutes at room temperature. The
samples were then fixed, permeabilized, and labeled with a fluorescently conjugated
monoclonal antibody (clone 16C2) directed against the serine 239 phosphorylated form of
VASP and, as a platelet identifier, CD61. Analysis was performed in a FACSCalibur flow
cytometer (Becton Dickinson, Mountain View, CA). The platelet reactivity index (PRI) was
calculated after subtracting background fluorescence, according to the manufacturer’s
Chang et al. Page 3
Thromb Res. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
recommendations using the formula PRI = [(MFI(PGE1)−MFI(PGE1+ADP))/MFI(PGE1)]×100,
where MFI is the mean fluorescence intensity.
HEPES-saline buffer was added as a control (i.e. no antagonist, 0% inhibition). The possible
agonist property of Ap4A on P2Y12 was tested by adding Ap4A to the tube incubated with
PGE1 in the absence of ADP.
To evaluate degradation and the possibility of generating biologically active metabolites of
Ap4A in the VASP assay, Ap4A was incubated with whole blood and the PGE1 reagent from
the VASP kit for 0, 3, 6 and 10 minutes. The mixture was centrifuged at 13,600 g for 1 minute
and the supernatant retrieved and stored at −80°C until analysis. Prior to analysis by high
performance liquid chromatography (HPLC), proteins were removed by perchloric acid
precipitation and the samples centrifuged (13,000 g) and filtered (0.45 µ nylon).
P2Y1-mediated cytosolic calcium increase measured by flow cytometry with the calcium
indicator FLUO-4
The ADP-dependent, P2Y1-mediated increase in platelet cytosolic calcium was measured by
detecting changes in FLUO-4 fluorescence (Fig. 1), as previously described[24]. In brief, one
part of citrated whole blood was added to 9 parts of a loading solution consisting of FLUO-4
(5 µM final concentration), CD41-PE-Cy5 (1:176 dilution in HEPES-saline buffer [10 mM
HEPES, 0.15 M NaCl, pH 7.4]) and probenecid (1 mM final concentration), and the mixture
was incubated for 30 minutes at room temperature. Fifteen µL of this mixture were added to
525 µL of HEPES-saline buffer, and the mixture analyzed by a FACSCalibur flow cytometer.
After obtaining a 30 second baseline recording, the acquisition was paused, and 60 µL of either
ADP (3 µM final concentration), Ap4A at various concentrations, or ADP (3 µM final
concentration) plus Ap4A at various concentrations were quickly added, the sample mixed,
and the acquisition resumed (total pause time less than 10 seconds). FLUO-4 fluorescence was
monitored for a total of 2 minutes. FLUO-4 fluorescence was plotted vs. time using FlowJo
version 7.2.2 (Tree Star, Ashland, OR) software. The mean FLUO-4 fluorescence of the
baseline 30 second interval and of 10 second post-stimulant intervals were calculated. The
cytosolic Ca2+ increase was calculated as the ratio of the maximal post-stimulant FLUO-4
fluorescence to the baseline FLUO-4 fluorescence. The percent inhibition of ADP-induced
calcium increase due to the addition of Ap4A was calculated relative to ADP (3 µM) plus
vehicle (HEPES-saline).
P2X1-mediated entry of extracellular calcium measured by flow cytometry with the calcium
indicator FLUO-4
P2X1 receptors are ligand-gated ion channels which, when triggered, cause cytosolic Ca2+ to
increase by allowing entry of extracellular Ca2+ (Fig. 1). Measurement of P2X1-mediated entry
of extracellular Ca2+ with FLUO-4 differed from measurement of P2Y1-mediated increase in
cytosolic Ca2+ from intracellular stores in that 1) blood was collected in PPACK (0.3 mM)
rather than sodium citrate, to preserve physiologic extracellular Ca2+ levels, 2) apyrase (1.8
µM final concentration) was added immediately upon blood collection to degrade any ATP
present, thereby avoiding P2X1 receptor desensitization.[1,25], 3) prior to loading platelets
with FLUO-4, PRP was separated from erythrocytes in order to minimize erythrocyte-derived
nucleotides, and 4) FLUO-4-loaded platelets were diluted and analyzed in buffer containing
Ca2+ (2 mM) rather than in Ca2+-free buffer to provide physiologic levels of extracellular
Ca2+. Platelets in apyrase-treated, PPACK-anticoagulated PRP were loaded with FLUO-4 for
30 minutes in the presence of probenecid (1 mM), diluted in HEPES-saline buffer containing
2 mM CaCl2, and then baseline FLUO-4 fluorescence was obtained. P2X1-dependent entry of
extracellular Ca2+ was demonstrated by increased FLUO-4 fluorescence upon addition of the
specific P2X1 receptor agonist β,γ-CH2-ATP (20 µM), and the absence of this increase when
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platelets were resuspended in 1 mM EGTA, HEPES-saline buffer, or prepared without addition
of apyrase to preserve P2X1 activity. FLUO-4 fluorescence after addition of various
concentrations of Ap4A to this system was used to evaluate agonist activity on P2X1. In
addition, the ability of Ap4A (50 µM) to block P2X1 activation by β,γ-CH2-ATP (20 µM) was
tested. To ensure that the increase of cytosolic Ca2+ in these experiments was not due to
spurious P2Y1-mediated Ca2+ increase, some experiments were done in the presence of 1 mM
EGTA in HEPES-saline buffer, MRS2179 (100 µM, a P2Y1 receptor antagonist),[26,27] or
both.
Statistical analysis
The results were analyzed by GraphPad Prism software, version 4.00 for Windows (GraphPad
Software, San Diego, CA). All results are expressed as mean ± standard error of the mean
(SEM). Student's t-test was used to determine statistical significance when two groups of data
were compared. One way ANOVA and Bonferroni’s multiple comparison test were used when
three or more groups of data were compared.
Results
Inhibition of ADP-induced platelet aggregation
Ap4A inhibited maximal ADP-induced platelet aggregation and, at a high concentration (100
µM), prevented secondary aggregation and resulted in disaggregation (Fig. 2A). Dose-
dependent inhibition of ADP-induced platelet aggregation determined by the 96-well
microplate method is shown in Fig. 2B. The IC50 was 9.8 ± 2.8 µM.
Agonist and antagonist properties of Ap4A on P2Y12 receptors
The unstimulated baseline VASP phosphorylation MFI was obtained by treating platelets with
PGE1 in all experiments (Fig. 3). As expected, the addition of 3 µM ADP reduced VASP
phosphorylation (Fig. 3, open bar). Ap4A was added to attenuate this ADP effect as a potential
antagonist (in comparison with PGE1+ADP) or to reduce VASP phosphorylation by itself as
a potential agonist (in comparison with PGE1 alone). VASP phosphorylation in the presence
of 15.6 µM Ap4A (Fig. 3, hash-marked grey bar) was significantly reduced compared to that
obtained with PGE1 alone (Fig. 3, grey bar, p <0.01), suggesting that Ap4A acts as an agonist
of P2Y12. However, increasing the concentration of Ap4A up to 250 µM did not further reduce
PGE1-stimulated VASP phosphorylation (p >0.05 for the comparison among three Ap4A
concentrations tested), suggesting that Ap4A is only a partial agonist of P2Y12. Addition of
the specific P2Y12 antagonist AR-C69931 (10 µM) blocked Ap4A-induced reduction of VASP
phosphorylation (data not shown), indicating that this agonist effect of Ap4A is mediated
through P2Y12. HPLC analysis of Ap4A incubated with whole blood under the same conditions
used in the VASP assay for up to 10 min (i.e., the incubation time of the VASP assay) showed
no loss of Ap4A (data not shown). Likewise, the normal degradation products of Ap4A, AMP
and ATP, were low and did not increase over time and ADP was not detected (data not shown).
Thus, the agonist effect of Ap4A on P2Y12 did not appear to be mediated by a metabolite of
Ap4A.
In the presence of increasing concentrations of Ap4A, there was a dose-dependent blockade of
ADP’s effect, resulting in higher levels of phosphorylated VASP (Fig. 3, hash-marked open
bars). The calculated PRI for the inhibition of VASP phosphorylation induced by ADP relative
to the maximal VASP phosphorylation without ADP was 89.5 ± 2.1%, 74.7 ± 1.0%, 61.5 ±
9.4%, and 48.9 ± 6.2% for 0, 15.6, 62.5, and 250 µM Ap4A, respectively. Thus, the IC50 for
Ap4A inhibition of the ADP-induced, P2Y12-mediated response was >250 µM.
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Agonist and antagonist properties of Ap4A on P2Y1 receptors
ADP stimulation of P2Y1 results in platelet shape change which can be measured by the change
in transmittance in an aggregometer. Ap4A inhibited 3 µM ADP-induced platelet shape change
in a dose-dependent manner (Fig. 4A, estimated IC50 200 µM). ADP stimulation of P2Y1 also
results in increases in cytosolic Ca2+ (Fig. 1). Therefore, we evaluated the effect of Ap4A on
the ADP-induced increase in cytoplasmic Ca2+. In platelets prepared in the absence of apyrase,
i.e. without preserving the activity of P2X1, and without addition of extracellular Ca2+, 3 µM
ADP produced an approximately 3.5-fold increase in FLUO-4 fluorescence and this increase
was inhibited by Ap4A in a dose-dependent manner (Fig. 4B), with an IC50 of 40.8 ± 12.3 µM.
That a higher concentration of Ap4A was required for 50% inhibition ADP-stimulated platelet
shape change (~200 µM) than was required for inhibition of ADP-stimulated increase in
cytoplasmic Ca2+ from intracellular stores (~40 µM) is not surprising since platelet shape
change is likely triggered by a low threshold increase in cytoplasmic Ca2+, and thus would
require an amount of Ap4A that reduces the cytoplasmic Ca2+ increase by greater than 50%.
Thus, as evidenced by two independent assays, platelet shape change and increase in cytosolic
Ca2+, Ap4A is an antagonist of P2Y1 receptors.
Under the same conditions, but in the absence of ADP, Ap4A at concentrations up to 250 µM
did not induce an increase in cytoplasmic Ca+2 as measured by the FLUO-4 fluorescence ratio
in comparison with HEPES-saline vehicle control (1.18 ± 0.09 vs. 1.09 ± 0.06, mean ± SEM,
n = 5, p = 0.161). Thus, Ap4A is not an agonist of P2Y1.
Agonist and antagonist properties of Ap4A on P2X1 receptors
Platelet P2X1 function was not a factor in the platelet aggregation, shape change, P2Y1 release
of internal Ca2+, and P2Y12-mediated VASP assays described above since activity of P2X1
was not preserved under the conditions used to isolate platelets for those assays. However,
when platelets were prepared using protocols to protect P2X1 from desensitization and
suspended in buffer containing 2 mM Ca2+, Ap4A at 0.1 µM and higher concentrations induced
an increase in platelet intracellular Ca2+ (Fig. 5A). For Ap4A concentrations between 0.1 and
10 µM, this increase was entirely due to the P2X1-mediated entry of extracellular Ca2+, because
it was eliminated when platelets were resuspended in buffer containing EGTA instead of
Ca2+ (Fig. 5). Moreover, failure of the P2Y1 antagonist MRS2179 at 100 µM to inhibit the
Ap4A-stimulated rise in Ca2+ (Fig. 5A) indicated that this rise was not due to direct or indirect
stimulation of P2Y1. Similarly, the majority of the cytoplasmic Ca2+ rise produced by 50 µM
Ap4A was eliminated in the presence of EGTA and could not be blocked by MRS2179.
However, there was a small, but statistically significant component of the Ca2+ increase at 50
µM Ap4A that was not blocked by EGTA but was blocked by MRS2179, indicating some
P2Y1-mediated contribution at this high Ap4A concentration. The biphasic dose-response
observed for Ap4A (Fig. 5A) was also observed with the specific P2X1 receptor agonist β,γ-
CH2-ATP (data not shown). Finally, MRS2159, a selective P2X1 antagonist [28], added in
parallel with Ap4A, dose-dependently blocked Ap4A-stimulated Ca2+ entry into platelets (Fig.
6), demonstrating that the Ap4A-induced rise in platelet cytoplasmic Ca2+ requires P2X1.
Taken together, these data show that Ap4A is an agonist of platelet P2X1 receptors.
When 50 µM Ap4A was added to a submaximal concentration of a selective P2X1 agonist, 20
µM β,γ-CH2-ATP, the post-stimulation FLUO-4 MFI was higher than with 20 µM β,γ-CH2-
ATP alone (4.43 ± 0.20 vs. 3.57 ± 0.47, p = 0.034, n = 3). Thus, there was no evidence that
Ap4A is a P2X1 antagonist, and the enhanced response suggested that Ap4A augmented the
P2X1 agonist effect of 20 µM β,γ-CH2-ATP.
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Discussion
The major findings of this study are that Ap4A, a known constituent of platelet dense granules,
is: a) an antagonist of platelet P2Y1 and P2Y12 receptors, where it inhibits the effects of the
agonist ADP, b) an agonist of P2X1 receptors, and c) a partial agonist of P2Y12 receptors.
These stimulating and inhibiting activities are summarized in Table 1.
Antagonist effects of Ap4A on platelet P2Y1 and P2Y12 receptors
Previously published studies showed that Ap4A and its analogs inhibit ADP-induced platelet
aggregation and several aspects of platelet activation including release action, cytoplasmic
calcium mobilization, thromboxane production, fibrinogen binding, and platelet factor 3
activities[14]. This inhibition of platelet functions was considered to be mediated through the
P2T pathway[14], a poorly defined term used before the currently known purinergic receptors,
P2X1, P2Y1 and P2Y12, were cloned and their functions well characterized. In the current
study, consistent with these previous reports [14], we found that Ap4A inhibits 3 µM ADP-
induced platelet aggregation. The platelet disaggregation that was observed with 100 µM
Ap4A (Fig. 2) suggests that Ap4A inhibited the P2Y12 pathway. On the other hand, we also
found that Ap4A inhibits 3 µM ADP-induced platelet shape change (Fig. 4A), which is mainly
mediated by P2Y1[1,25].
ADP-induced platelet signaling through P2Y1 and P2Y12 receptors can be examined by
specific assays, i.e. ADP-induced calcium increase for P2Y1 receptors and ADP-induced
VASP phosphorylation decrease for P2Y12 receptors (Fig. 1). In the present study, 3 µM ADP-
induced platelet cytosolic Ca2+ rise was inhibited by Ap4A with an IC50 of 40.8 µM (Fig. 4B).
This result confirmed that Ap4A is a P2Y1 antagonist. In addition, the decrease in ADP-induced
VASP phosphorylation was inhibited by Ap4A in a dose-dependent manner (Fig. 3). While
Ap4A inhibition of ADP-stimulated, P2Y1-mediated increase in cytosolic calcium was
measured within seconds of adding Ap4A and ADP to cells, the P2Y12 mediated VASP
response was measured 10 minutes after adding Ap4A to whole blood, raising the possibility
that metabolites of Ap4A, and not Ap4A per se may be responsible for effects on P2Y12.
However, this appears unlikely since HPLC analysis showed no breakdown of Ap4A when
incubated under VASP assay conditions. Taken together, these results indicate that Ap4A is
an antagonist for both P2Y1 and P2Y12 receptors. Such dual specificity on platelet P2Y1 and
P2Y12 receptors has been recently reported for other compounds[29,30].
Although 3 µM ADP was used as the stimulant in all experiments, the IC50 for inhibition of
platelet aggregation (9.8 ± 2.8 µM) was 4-fold lower than the IC50 for the inhibition of the
P2Y1-mediated increase of cytosolic Ca2+ (40.8 ± 12.3 µM) and more than 25-fold lower than
the IC50 for the P2Y12-mediated decrease in VASP phosphorylation (>250 µM). Our results
are similar to the findings of Cattaneo et al. [29] who reported that both MRS2298 and
MRS2496 inhibited ADP-induced platelet aggregation, shape change and P2Y1-mediated
Ca2+ increase but, at higher concentrations, these compounds also partially inhibited ADP-
induced decrease of cAMP, possibly via the P2Y12 pathway. Furthermore, Cattaneo et al.
[29] reported that the IC50s of MRS2298 and MRS2496 for inhibition of platelet aggregation
were lower than those for cytosolic Ca2+ increase and shape change. These data suggest
synergism between P2Y1 and P2Y12 antagonism. Indeed, the synergism of antagonism
between P2Y1 and P2Y12 receptors using selective antagonists for each receptor has been well
documented in vitro[31]. The present findings and those of Cattaneo et al.[29] demonstrate
that synergism of inhibition may occur for a single compound with dual receptor antagonist
properties. However, the present findings are the first report of an endogenous molecule
released by platelets that has a dual and synergistic inhibitory effect on both P2Y1 and
P2Y12 receptors. This synergism may be explained, at least in part, by the recently reported
reciprocal cross-talk between P2Y1 and P2Y12 receptors[32,33].
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Agonist effects of Ap4A on platelet P2Y12 but not P2Y1 receptors
In addition to the inhibitory effects of Ap4A on P2Y1 and P2Y12 pathways, we demonstrated
that Ap4A attenuated PGE1-stimulated VASP phosphorylation (Fig. 3). This attenuation was
prevented by AR-C69931, demonstrating specificity for P2Y12. These data indicates that
Ap4A either directly or indirectly (e.g., via metabolites) results in platelet P2Y12 activation.
However, our study of metabolites after incubation with whole blood suggests such effects
result directly from Ap4A rather than its metabolites.
The apparently opposing effects of Ap4A, as a weak agonist of P2Y12, causing a decrease in
VASP phosphorylation, and at the same time as a partial antagonist of P2Y12, blocking ADP-
stimulated decrease in VASP phosphorylation are both explained by a weak and inefficient
interaction of Ap4A with P2Y12. When added alone, the effect of Ap4A on VASP
phosphorylation is maximal at 15.6 µM, suggesting saturation of Ap4A binding to P2Y12 at
this Ap4A concentration and higher. However, even with saturating concentrations of Ap4A,
only small decreases in VASP phosphorylation were observed, indicating the Ap4A-P2Y12
interaction triggers only a weak downstream signal. In contrast, ADP by itself causes a large
decrease in VASP phosphorylation, suggesting efficient coupling of ADP-P2Y12 with
downstream events. Thus, the interaction of Ap4A with P2Y12, while causing weak
downstream signals, prevents ADP from triggering stronger signals with larger decreases in
VASP phosphorylation. The fact that very high concentrations of Ap4A (250 µM) are required
to block the ADP effect on VASP suggests that Ap4A binding is reversible and that even
binding of small amounts of ADP, as might occur over the 10 minute VASP assay incubation
is sufficient to trigger a strong P2Y12 coupled response.
Although Ap4A and other diadenosine polyphosphates have been reported to activate P2Y1
receptors in other cell types[34,35], their agonist activity on platelet P2Y1 receptors is
unknown. We found that Ap4A stimulation did not result in P2Y1-mediated increase of platelet
cytosolic Ca2+ and, therefore, does not act as a platelet P2Y1 receptor agonist.
Agonist effects of Ap4A on platelet P2X1 receptors
It is well known that Ap4A is an agonist for P2X receptors in rat vas deferens and human
urinary bladders[17,36]. In platelets, Sage et al.[4] showed that Ap4A may induce a rise in
cytosolic Ca2+ and suggested that this was mediated by P2X1. Such an Ap4A-induced platelet
cytosolic Ca2+ rise was also observed in our study with extracellular Ca2+ available, but was
obliterated when extracellular Ca2+ was removed by the chelating agent EGTA (Fig. 5A).
These data confirm that the cytosolic Ca2+ increase resulted solely from an influx of
extracellular Ca2+, i.e. a P2X-mediated effect (Fig. 1). Moreover, MRS2159, a selective
P2X1 antagonist[28], blocked the Ap4A-induced influx of extracellular Ca2+, demonstrating
Ap4A is a platelet P2X1 agonist. Although Ap4A and other adenosine polyphosphates can be
both agonists and antagonists of P2Y1 and P2Y12 receptors, the present study has demonstrated
that Ap4A functions only as an agonist, not an antagonist, for platelet P2X1 receptors.
Possible pathophysiologic roles of Ap4A
The plasma concentration of Ap4A has been reported to range from 0.33 − 1.0 µM[8,10,13].
However, in the platelet-rich microenvironment where a thrombus is formed or high shear
force is generated by vessel damage, the local concentration of Ap4A may reach up to 100 µM
as a result of dense granule release by involved platelets[8,10,13]. The present study has
demonstrated that 0.1–1 µM Ap4A has significant agonist effects on platelet P2X1 receptors.
In addition, Ap4A inhibits ADP-induced aggregation and cytosolic Ca2+ increase with IC50s
of 9.8 ± 2.8 and 40.8 ± 12.3 µM, respectively. Although the concentrations of Ap4A required
to antagonize ADP effects on platelet P2Y1 and P2Y12 receptors are high compared to ADP,
it is well known that Ap4A and other diadenosine polyphosphates are more stable than ADP
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and ATP[10]. Whereas ADP is rapidly inactivated by ecto-nucleotidase[37], Ap4A is more
resistant to hydrolysis[10] and therefore attains higher concentrations than ADP in plasma and
in the local thrombotic microenvironment. Whether this high concentration can be reached in
any pathophysiological conditions is unclear therefore the pathophysiologic role of high
concentration Ap4A is speculative.
Pharmacologic Perspectives
Ap4A is the backbone of some chemical derivatives being developed as potential antiplatelet
agents. In vitro antiplatelet[14,38] and in vivo antithrombotic effects[39,40] of Ap4A and its
derivatives have been reported, and antithrombotic potency is improved after certain chemical
structure modifications[14,38]. The current study shows that Ap4A has antagonist effects for
platelet P2Y12 receptors, the target of several effective antithrombotic agents including
clopidogrel and prasugrel[41]. Ap4A derivatives, while different in potencies and selectivity
towards platelet receptors (results to be published), may have antiplatelet effects comparable
to clinically available drugs such as clopidogrel. In clinical studies[5], standard doses of the
widely-used, FDA-approved P2Y12 antagonist clopidogrel reduced VASP PRI to 61.1 ± 17%
mean ± SD) of maximal. In the present study, 62.5 µM Ap4A resulted in a similar reduction
of VASP PRI, to 61.5 ± 9.4%. Thus, Ap4A released as a result of initial platelet activation may
block subsequent activation of platelets to the same degree as pharmacological doses of
clopidogrel. Furthermore, in the present study 250 µM Ap4A reduced VASP PRI to 48.9 ±
6.2%.
The potential advantage of Ap4A and its derivatives as therapeutic antiplatelet agents is that,
unlike clopidogrel, prasugrel, or other P2Y12 antagonist in development, they also have, as
demonstrated in the present study, a synergistic inhibitory effect on platelet P2Y1 receptors.
One potential concern of using Ap4A or its derivatives as antithrombotic agents might be their
action on platelet P2X1 receptors. Recent studies indicate that P2X1 has an important role in
platelet activation, particularly under conditions of shear stress[19]. Nevertheless, the present
study on the mechanism of platelet inhibition by Ap4A provides a framework for future
development of Ap4A-derived antiplatelet agents. Chemically modified Ap4A derivatives may
be compared to Ap4A for their selective potency on platelet purinergic receptors.
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Figure 1. Platelets express three purinergic receptors, P2Y1, P2Y12 and P2X1
The ligand is ADP for P2Y1 and P2Y12, and ATP for P2X1. P2X1 is a ligand-gated ion channel
which allows extracellular Ca2+ to shift into the cytoplasm upon activation. ADP binding to
the P2Y1 receptor induces activation of phospholipase C β (PLC-β), which, via inositol
triphosphate (IP3), subsequently leads to release of cytoplasmic Ca2+ pools. Both P2X1 and
P2Y1 activation cause cytosolic Ca2+ increase, which in the present study was measured by
flow cytometry with the Ca2+ indicator, FLUO-4. ADP binding to platelet P2Y12 receptors
results in a decrease of cytoplasmic cAMP by inhibiting adenylyl cyclase. cAMP subsequently
leads, via protein kinase A (PKA), to phosphorylation of vasodilator stimulated phosphoprotein
(VASP), which was measured by flow cytometry.
Chang et al. Page 12
Thromb Res. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Ap4A inhibits ADP-induced platelet aggregation
A, Platelet aggregation induced by 3 µM ADP was inhibited by Ap4A in a dose-dependent
manner. At 100 µM Ap4A complete platelet disaggregation was observed. The experiments
were performed in a Chrono-log® aggregometer. B, Dose response curve for Ap4A inhibition
of 3 µM ADP-induced platelet aggregation (mean ± SEM, n = 3). The results were obtained
with the 96-well microplate reader method.
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Figure 3. Ap4A reduces VASP phosphorylation and attenuates the ADP-induced decrease in VASP
phosphorylation
Platelets were treated with PGE1 in every experiment, and the resultant MFI was used as
unstimulated baseline (see Materials and Methods for details). As expected, the addition of 3
µM ADP reduced VASP phosphorylation (open bar). This ADP-induced decrease in VASP
phosphorylation was attenuated by Ap4A in a dose dependent manner (hash-marked open bars),
# p <0.05 compared with PGE1 plus ADP (open bar). Ap4A in the absence of ADP addition
resulted in a decrease in VASP phosphorylation but not in a dose-dependent manner (hash-
marked grey bars, * p <0.05, ** p <0.01 compared with PGE1 alone. There was no statistically
significant difference among the three tested concentrations of Ap4A. The data (mean ± SEM,
n = 3) were analyzed by one way ANOVA and Bonferroni’s multiple comparison test.
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Figure 4. Ap4A inhibits ADP-induced platelet shape change and cytosolic Ca2+ increase
A, Platelet shape change (upward deflection) induced by 3 µM ADP was inhibited by Ap4A
in a dose-dependent manner. Note that there was no platelet aggregation (downward deflection)
after shape change because EDTA (10 mM) was mixed with PRP. Results shown are
representative of 3 such experiments. B, Dose response curve of Ap4A inhibition of 3 µM
ADP-induced intracellular Ca2+ increase, measured by flow cytometry with the calcium
indicator FLUO-4 (mean ± SEM, n = 4).
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Figure 5. Dose response of Ap4A-induced, P2X1-mediated cytosolic Ca2+ increase. A
The experiments were performed under conditions specific for P2X1 (see Materials and
Methods for details), with the indicated buffers: (■) 2 mM Ca2+; (♦) 1 mM EGTA, no Ca2+;
(△) 2 mM Ca2+ plus 100 µM MRS2179; (○) 1 mM EGTA plus 100 µM MRS2179, no Ca2+.
Results are mean ± SEM, n = 4.
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Figure 6. Dose-dependent MRS2159 inhibition of 0.5 µM Ap4A- and 1 µM β,γ-CH2-ADP-induced
entry of extracellular Ca2+ into platelets
FLUO-4-loaded platelets suspended in 2 mM Ca2+ buffer were stimulated with either Ap4A
0.5 µM (black bars) or 1 µM β,γ-CH2-ATP (grey bars) in the presence of 0, 6.25, 25, or 100
µM MRS2159. Dependence on extracellular calcium is shown by results of control samples
suspended in 2 mM EDTA without Ca2+ and stimulated with Ap4A 0.5 µM (open bar). Results
are mean ± SEM, n=3. Abbreviations: EDTA, ethylene diamine tetraacetic acid; nd, not done.
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Table
Summary of Ap4A platelet stimulating and inhibiting activities.
Assay Ap4A Agonist Activity Ap4A Antagonist Activity
(inhibition of ADP
or β,γ-CH2-ATP)*
Aggregation
(P2Y1 and P2Y12
mediated)
no activation at up to 250 µM IC50 9.8 ± 2.8 µM
Shape Change
(P2Y1 mediated)
no activation at up to 250 µM IC50 ~200 µM
P2Y1 release of
internal Ca2+
no activation at up to 100 µM IC50 40.8 ± 12.3
P2Y12-mediated
VASP
maximal at 15.6 µM IC50 >250 µM
P2X1 entry of
external Ca2+
EC50 ~0.3 µM (biphasic curve) No inhibition at 50 µM
*
Ap4A antagonist activity was determined relative to 3 µM ADP stimulation of platelet aggregation, shape change, P2Y1 release of internal Ca2+,
and P2Y12-mediated VASP and relative to 20 µM β,γ-CH2-ATP stimulation of P2X1 entry of external Ca2+.
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